Last week Purdue Pharma released unexpected data on a new product in development: an extended release, acetaminophen-free, hydrocodone pain medication. Purdue's press release claims to have some degree of abuse deterrence incorporated into it. A major point of contention over recently launched competitor Zogenix's (NASDAQ:ZGNX) Zohydro is that it does not. In this article, I'll look to other examples of abuse deterrent formulations to try and understand how the FDA will handle this increasing political situation.
Becoming a political issue
Calls for removal of Zohydro from the market have been increasing since the FDA approved the drug. Despite a panel vote recommending against the drug's approval due to its lack of abuse deterrence, the FDA finally granted authorization....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|